CHROMITOPE SODIUM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHROMITOPE SODIUM (CHROMITOPE SODIUM).
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
| Metabolism | Chromium-51 is slowly excreted primarily via urine (about 80% over 3 weeks) with small amounts in feces. A small fraction is retained in the body with a long biological half-life. No enzymatic metabolism; remains as inorganic chromate or bound to hemoglobin until RBC breakdown. |
| Excretion | Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%). |
| Half-life | Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours). |
| Protein binding | 93-97% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 0.15-0.25 L/kg (low, primarily in extracellular fluid). |
| Bioavailability | Oral: 50-70% (first-pass effect); IM: 75-90%. |
| Onset of Action | IV: immediate (2-5 minutes); oral: 30-60 minutes. |
| Duration of Action | IV: 4-6 hours; oral: 6-8 hours. Extended-release: 12-24 hours. |
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for GFR; however, consider risk of bleeding in severe renal impairment due to chromate content. |
| Liver impairment | No specific adjustments for Child-Pugh class; use with caution in severe hepatic impairment. |
| Pediatric use | Weight-based: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) intravenously, minimum 0.5 mCi (18.5 MBq). |
| Geriatric use | No specific adjustments; dose based on renal function and clinical condition. Use lowest effective dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHROMITOPE SODIUM (CHROMITOPE SODIUM).
| Breastfeeding | Interrupt breastfeeding for at least 4 hours after administration to reduce infant radiation exposure. M/P ratio unknown. |
| Teratogenic Risk | No human data; animal studies not available. As a radiopharmaceutical, the radiation dose is minimized, but risks cannot be ruled out. Avoid use in pregnancy unless benefit outweighs unknown fetal risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not applicable. No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to chromate or any component of the formulation.","Pregnancy (relative contraindication; use only if necessary)."]
| Precautions | ["Radiopharmaceutical: ensure proper handling and disposal to minimize radiation exposure to patients and healthcare personnel.","Pregnancy: consider radiation dose to fetus; use only if benefits outweigh risks.","Lactation: discontinue breastfeeding temporarily after administration.","Hypersensitivity: rare allergic reactions possible; monitor for signs.","Do not use in patients with hemolytic anemia or recent blood transfusion (may yield inaccurate results)."] |
| Food/Dietary | No specific food interactions are known for Chromitope Sodium. However, patients should maintain adequate hydration before and after the procedure to promote renal excretion of the radiopharmaceutical. |
Loading safety data…
| Maintain hydration to enhance renal clearance. Monitor for signs of hypersensitivity reaction. |
| Fertility Effects | No known effects on fertility. |
| Clinical Pearls | Chromitope Sodium (sodium chromate Cr-51) is a diagnostic radiopharmaceutical used to label red blood cells for determination of red cell mass and survival studies. Administer intravenously with careful dose calibration. Assess patient for prior allergic reactions to chromium compounds. Ensure adequate hydration post-administration to facilitate clearance. Monitor blood counts if repeated studies are performed due to radiation exposure. |
| Patient Advice | This medication is a radioactive tracer used to measure the volume and lifespan of your red blood cells. · You will receive a small dose of radiation; the benefits of the test outweigh the risks. · Drink plenty of fluids after the procedure to help eliminate the radioactive material from your body. · Inform your healthcare provider if you are pregnant, breastfeeding, or have a history of allergies. · Avoid close contact with pregnant women and young children for 24 hours after the test. |